• No results found

18 results with keyword: 'allogeneic stem transplantation young patients diagnosed multiple myeloma'

“No” for the allogeneic stem cell transplantation in young patients diagnosed with multiple myeloma

The incidence of acute and chronic graft-versus-host disease in multiple myeloma patients subjected to allogeneic stem cell transplantation GVHD Schilling et al... from the

Protected

N/A

7
0
0
2021
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

: Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a

Protected

N/A

12
0
0
2020
Limited progress in closing the mortality gap for Aboriginal and Torres Strait Islander Australians of the Northern Territory

If Aboriginal and Torres Strait Islander childhood mortality (across ages 0–14 years) were to fall to the same rates experienced by the Australian population as a whole in

Protected

N/A

7
0
0
2021
What is STEM Education? Why is STEM Education Important in the 21 st Century?

Union York In the Central Pennsylvania Region, 50 STEM occupations have been identified and each of the sub-regions has been evaluated for their potential STEM employment

Protected

N/A

140
0
0
2021
Characteristics and outcomes of patients with multiple myeloma : Data from a developing country

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation:

Protected

N/A

5
0
0
2020
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome

The evidence for autologous hematopoietic stem cell transplantation (HSCT) for upfront treatment in patients who have newly diagnosed multiple myeloma includes several

Protected

N/A

18
0
0
2021
Recent advances in therapy for multiple myeloma in transplant eligible patients: Literature of review

dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II

Protected

N/A

7
0
0
2020
Myeloma Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case- matched study from the European Group for Blood and

Protected

N/A

8
0
0
2021
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Particularly for younger and fit patients with newly diagnosed multiple myeloma (NDMM), the melphalan high-dose chemotherapy (HDCT) with autologous stem cell transplantation

Protected

N/A

10
0
0
2021
Multiple myeloma: the disease and its treatment

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.. A phase II trial of

Protected

N/A

19
0
0
2020
MULTIPLE MYELOMA MEDICAL SCIENTIFIC ADVISORY GROUP (MSAG) PANEL MEMBERS.

Harousseau, J.L., et al., Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:

Protected

N/A

41
0
0
2021
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. Multiple Myeloma. Version NCCN.org. Continue

followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase

Protected

N/A

68
0
0
2021
Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase

Protected

N/A

9
0
0
2020
Immunotherapy in Myeloma

Even if allogeneic stem cell transplantation has not found its definitive role in the treatment of multiple myeloma, our understanding of the immunological interaction of myeloma

Protected

N/A

126
0
0
2022
Fundamentals in the Management of Multiple Myeloma

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: result of an IFM phase

Protected

N/A

9
0
0
2020
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem- cell

Protected

N/A

10
0
0
2021
60 Review. Abstract. The Past

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II

Protected

N/A

11
0
0
2021
Continuing medical education activity in American Journal of Hematology

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II

Protected

N/A

11
0
0
2021

Upload more documents and download any material studies right away!